The annual revenue of iTeos Therapeutics, a clinical-stage biopharmaceutical company focused on advancing novel immuno-oncology therapeutics, varies significantly from year to year depending on the timing of major licensing agreements, upfront collaboration payments, and milestone achievements associated with pharmaceutical partnerships. Financial reporting records indicate that the company has posted varying annual figures, such as approximately thirty-five million dollars during recent fiscal periods following strategic partnership inflows, though revenue generation remains secondary to research expenditure as the company continues advancing its robust pipeline of antibody treatments through mid-stage and late-stage clinical trials.